

# SCTbio and CCRM Nordic Form Strategic Partnership to Accelerate Advanced Therapy Development

January 20, 2025

- **A new collaboration between SCTbio and CCRM Nordic aims to bridge critical gaps in advanced therapy development and commercialization.**

## Press Release, Prague, Czech Republic, January 20, 2025

SCTbio, a leading provider of cGMP manufacturing services for cell-based products, today announced a strategic partnership with CCRM Nordic, an organization dedicated to accelerating the commercialization of regenerative medicine technologies and cell and gene therapies.

This collaboration coincides with a pivotal time for the cell and gene therapy industry, as the sector faces several challenges that put focus and demand on driving efficiency in development pathways. With increasing regulatory approvals and the first treatment for solid tumours approved, there is growing clinical evidence supporting advanced therapies, which shows promise for the future of these new technologies. However, challenges remain in scaling production and controlling costs. The partnership will combine SCTbio's expertise in cGMP manufacturing with CCRM Nordic's comprehensive infrastructure and analytical capabilities to provide end-to-end support for early-stage cell therapy companies.

"This partnership represents more than just combining capabilities – it's about creating a seamless pathway from innovation to patient impact," explained Luděk Sojka, CEO of SCTbio. "By removing traditional barriers between development stages, we're enabling the next generation of cell therapies to move forward with greater speed and certainty."

The partnership will leverage CCRM Nordic's future state-of-the-art 3,000 square meter laboratory facilities for analytical and process development, with plans for a GMP facility to be established in 2026. This infrastructure, combined with SCTbio's established manufacturing services, will create a robust ecosystem for the development and commercialization of advanced therapy medicinal products (ATMPs).

"Collaboration is essential to advance the cell therapy field," said Fredrik Wessberg, CEO of CCRM Nordic. "This partnership with SCTbio strengthens our ability to support innovative companies and accelerate the development of next-generation cell and gene therapies, ultimately bringing life-changing treatments to patients faster."

The alliance will focus on supporting phase I/II cell therapy companies, providing them with:

- integrated process development and manufacturing solutions
- comprehensive analytical services
- business strategy support
- access to global industry networks
- access to a 150-strong apheresis network
- logistics services for starting materials and final product

About CCRM Nordic

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs. For more information, please visit the company's website at [www.ccrmnordic.se](http://www.ccrmnordic.se).

**Business contact:**  
**Pascale Charbonnel**  
**Chief Business Officer**  
**M: +420 720 029 922**  
**E: [partnering@sctbio.com](mailto:partnering@sctbio.com)**